Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS
WHAT IS ALREADY KNOWN ON THIS TOPIC
Discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be followed by inflammatory reactivation, even in older patients, but the age threshold at which this risk becomes substantially attenuated remains unclear.
In this propensity score-matched, prospective cohort of people with MS aged ≥50 years, inflammatory outcomes after DMT discontinuation vary by age and treatment mechanism, with attenuation of risk in individuals aged >60 years and among those discontinuing anti-CD20 therapies.
Age and treatment mechanism may help inform individualised risk stratification when considering DMT discontinuation in older people with MS.
The proportion of older people with multiple sclerosis (MS) is steadily increasing,1 likely due to better prognosis,2 advances in disease-modifying therapies (DMTs) and expanded access...
Source: JNNP - Current Issue · Published 13 Oct 2026 · Imported 17 Oct 2026
Read the article